Literature DB >> 28121086

Treatment of Patients with Cirrhosis.

Phillip S Ge1, Bruce A Runyon2.   

Abstract

Entities:  

Year:  2016        PMID： 28121086     DOI： 10.1056/NEJMc1612334

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  The Gastroenterologist's Guide to Preventive Management of Compensated Cirrhosis.

Authors:  Akshay Shetty; Jung Jun Yum; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-08

2.  Artificial intelligence to predict overall survivals of patients with cirrhosis and outcomes of variceal bleeding.

Authors:  Cem Simsek; Hasan Sahin; Ibrahim Emir Tekin; Taha Koray Sahin; Hatice Yasemin Balaban; Bulent Sivri
Journal:  Hepatol Forum       Date:  2021-05-21

Review 3.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

4.  Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.

Authors:  Yuko Murakami; Kazuo Sugiyama; Hirotoshi Ebinuma; Nobuhiro Nakamoto; Keisuke Ojiro; Po-Sung Chu; Nobuhito Taniki; Yoshimasa Saito; Toshiaki Teratani; Yuzo Koda; Takahiro Suzuki; Kyoko Saito; Masayoshi Fukasawa; Masanori Ikeda; Nobuyuki Kato; Takanori Kanai; Hidetsugu Saito
Journal:  BMC Cancer       Date:  2018-06-25       Impact factor: 4.430

Review 5.  Hepatocellular cancer pain: impact and management challenges.

Authors:  Nathaniel Christian-Miller; Catherine Frenette
Journal:  J Hepatocell Carcinoma       Date:  2018-07-19

6.  "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Hepat Med       Date:  2019-09-02

7.  Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study.

Authors:  Wei-Fan Hsu; Shi-Hang Yu; Jaw-Town Lin; Jaw-Ching Wu; Ming-Chih Hou; Yi-Hsiang Huang; Chun-Ying Wu; Cheng-Yuan Peng
Journal:  Gastroenterol Res Pract       Date:  2019-10-10       Impact factor: 2.260

8.  Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis.

Authors:  Tianyue Zhang; Jingya Xu; Lingxia Ye; Xiling Lin; Yufeng Xu; Xiaowen Pan; Xifang Weng; Chuyu Ye; Longjiang Fan; Yuezhong Ren; Peng-Fei Shan
Journal:  J Cancer       Date:  2021-03-15       Impact factor: 4.207

9.  ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway.

Authors:  Qi Liu; Chengqian Lv; Qianqian Huang; Lei Zhao; Xiaoli Sun; Dandan Ning; Jingyang Liu; Yanan Jiang; Shizhu Jin
Journal:  Cell Death Discov       Date:  2022-02-08

Review 10.  The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.

Authors:  Dishen Chen; Thanh H Le; Haleh Shahidipour; Scott A Read; Golo Ahlenstiel
Journal:  Cells       Date:  2019-10-27       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.